246 related articles for article (PubMed ID: 26930506)
1. Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.
Hurabielle C; Pillebout E; Stehlé T; Pagès C; Roux J; Schneider P; Chevret S; Chaffaut C; Boutten A; Mourah S; Basset-Seguin N; Vidal-Petiot E; Lebbé C; Flamant M
PLoS One; 2016; 11(3):e0149873. PubMed ID: 26930506
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib significantly decreases glomerular filtration rate.
Uthurriague C; Thellier S; Ribes D; Rostaing L; Paul C; Meyer N
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):978-9. PubMed ID: 24267914
[No Abstract] [Full Text] [Related]
3. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
4. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
Teuma C; Perier-Muzet M; Pelletier S; Nouvier M; Amini-Adl M; Dijoud F; Duru G; Thomas L; Fouque D; Laville M; Dalle S
Cancer Chemother Pharmacol; 2016 Aug; 78(2):419-26. PubMed ID: 27371224
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
6. Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents.
Vermassen T; Geboes K; De Man M; Laurent S; Decoene E; Lumen N; Delanghe J; Rottey S
Nephrol Dial Transplant; 2018 Mar; 33(3):402-408. PubMed ID: 28482048
[TBL] [Abstract][Full Text] [Related]
7. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
Vidal-Petiot E; Rea D; Serrano F; Stehlé T; Gardin C; Rousselot P; Peraldi MN; Flamant M
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):169-74. PubMed ID: 26795084
[TBL] [Abstract][Full Text] [Related]
9. Plasma cystatin C as a marker of renal function in patients with liver cirrhosis.
Randers E; Ivarsen P; Erlandsen EJ; Hansen EF; Aagaard NK; Bendtsen F; Vilstrup H
Scand J Clin Lab Invest; 2002; 62(2):129-34. PubMed ID: 12004928
[TBL] [Abstract][Full Text] [Related]
10. Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
Duncker D; Oswald H; Gardiwal A; Lüsebrink U; König T; Schreyer H; Klein G
J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):109-12. PubMed ID: 22837540
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
15. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.
Del Vecchio M; Ascierto PA; Mandalà M; Sileni VC; Maio M; Di Guardo L; Simeone E; Queirolo P
Future Oncol; 2015; 11(9):1355-62. PubMed ID: 25952781
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates.
Le Bricon T; Leblanc I; Benlakehal M; Gay-Bellile C; Erlich D; Boudaoud S
Clin Chem Lab Med; 2005; 43(9):953-7. PubMed ID: 16176176
[TBL] [Abstract][Full Text] [Related]
18. Is serum cystatin C a better marker than serum creatinine for monitoring renal function in pediatric intensive care unit?
Asilioglu N; Acikgoz Y; Paksu MS; Gunaydin M; Ozkaya O
J Trop Pediatr; 2012 Dec; 58(6):429-34. PubMed ID: 22529319
[TBL] [Abstract][Full Text] [Related]
19. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure.
Damman K; van der Harst P; Smilde TD; Voors AA; Navis G; van Veldhuisen DJ; Hillege HL
Heart; 2012 Feb; 98(4):319-24. PubMed ID: 22038544
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
